{"id":30869,"date":"2019-05-15T12:00:00","date_gmt":"2019-05-15T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/"},"modified":"2019-05-15T12:00:00","modified_gmt":"2019-05-15T12:00:00","slug":"consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/","title":{"rendered":"Consensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme"},"content":{"rendered":"
\n
\n
\n

Biom\u00e9dicaments pour la CRSwNP avec ou sans asthme<\/h2>\n

De nouvelles th\u00e9rapies, telles que les biom\u00e9dicaments ciblant l\u2019inflammation de type 2, apparaissent comme des options de traitement pour les patients atteints de maladies respiratoires inflammatoires chroniques, r\u00e9pondant aux besoins des patients s\u00e9v\u00e8rement non contr\u00f4l\u00e9s. La majorit\u00e9 des patients atteints de rhinosinusite chronique avec polypes nasaux (CRSwNP) et plus de la moiti\u00e9 des patients asthmatiques pr\u00e9sentent une signature inflammatoire de type 2 au niveau de la muqueuse sinonasale et\/ou des poumons. <\/p>\n

EUFOREA a organis\u00e9 une r\u00e9union multidisciplinaire d\u2019un comit\u00e9 d\u2019experts afin de discuter du positionnement des biom\u00e9dicaments dans les parcours de soins des patients atteints de CRSwNP, avec ou sans asthme comorbide.<\/p>\n

T\u00e9l\u00e9chargez-le d\u00e8s maintenant pour obtenir l\u2019int\u00e9gralit\u00e9 des informations.<\/p>\n

ARTICLE EN ACC\u00c8S LIBRE<\/strong><\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n


\n
\n<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Biom\u00e9dicaments pour la CRSwNP avec ou sans asthme De nouvelles th\u00e9rapies, telles que les biom\u00e9dicaments ciblant l\u2019inflammation de type 2, apparaissent comme des options de traitement pour les patients atteints de maladies respiratoires inflammatoires chroniques, r\u00e9pondant aux besoins des patients s\u00e9v\u00e8rement non contr\u00f4l\u00e9s. La majorit\u00e9 des patients atteints de rhinosinusite chronique avec polypes nasaux (CRSwNP) et plus de la moiti\u00e9 des patients asthmatiques pr\u00e9sentent une signature inflammatoire de type 2 au niveau de la muqueuse sinonasale et\/ou des poumons. EUFOREA a organis\u00e9 une r\u00e9union multidisciplinaire d\u2019un comit\u00e9 d\u2019experts afin de discuter du positionnement des biom\u00e9dicaments dans les parcours de soins des patients atteints de CRSwNP, avec ou sans asthme comorbide. T\u00e9l\u00e9chargez-le d\u00e8s maintenant pour obtenir l\u2019int\u00e9gralit\u00e9 des informations. ARTICLE EN ACC\u00c8S LIBRE<\/p>\n","protected":false},"author":1,"featured_media":30889,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[266],"tags":[170,172,174,175,195,284],"class_list":["post-30869","news","type-news","status-publish","has-post-thumbnail","hentry","category-publications","tag-professionnels-de-sante","tag-asthme","tag-crswnp","tag-biotherapies","tag-maladies-respiratoires-chroniques-mrc","tag-publications"],"yoast_head":"\nConsensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Consensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme\" \/>\n<meta property=\"og:description\" content=\"Biom\u00e9dicaments pour la CRSwNP avec ou sans asthme De nouvelles th\u00e9rapies, telles que les biom\u00e9dicaments ciblant l\u2019inflammation de type 2, apparaissent comme des options de traitement pour les patients atteints de maladies respiratoires inflammatoires chroniques, r\u00e9pondant aux besoins des patients s\u00e9v\u00e8rement non contr\u00f4l\u00e9s. La majorit\u00e9 des patients atteints de rhinosinusite chronique avec polypes nasaux (CRSwNP) et plus de la moiti\u00e9 des patients asthmatiques pr\u00e9sentent une signature inflammatoire de type 2 au niveau de la muqueuse sinonasale et\/ou des poumons. EUFOREA a organis\u00e9 une r\u00e9union multidisciplinaire d\u2019un comit\u00e9 d\u2019experts afin de discuter du positionnement des biom\u00e9dicaments dans les parcours de soins des patients atteints de CRSwNP, avec ou sans asthme comorbide. T\u00e9l\u00e9chargez-le d\u00e8s maintenant pour obtenir l\u2019int\u00e9gralit\u00e9 des informations. ARTICLE EN ACC\u00c8S LIBRE\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Indications-for-Biological-treatment-in-patients-with-CRSwNP_0-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\\\/\",\"name\":\"Consensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"datePublished\":\"2019-05-15T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/news\\\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png\",\"width\":427,\"height\":280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Consensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Consensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/","og_locale":"fr_FR","og_type":"article","og_title":"Consensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme","og_description":"Biom\u00e9dicaments pour la CRSwNP avec ou sans asthme De nouvelles th\u00e9rapies, telles que les biom\u00e9dicaments ciblant l\u2019inflammation de type 2, apparaissent comme des options de traitement pour les patients atteints de maladies respiratoires inflammatoires chroniques, r\u00e9pondant aux besoins des patients s\u00e9v\u00e8rement non contr\u00f4l\u00e9s. La majorit\u00e9 des patients atteints de rhinosinusite chronique avec polypes nasaux (CRSwNP) et plus de la moiti\u00e9 des patients asthmatiques pr\u00e9sentent une signature inflammatoire de type 2 au niveau de la muqueuse sinonasale et\/ou des poumons. EUFOREA a organis\u00e9 une r\u00e9union multidisciplinaire d\u2019un comit\u00e9 d\u2019experts afin de discuter du positionnement des biom\u00e9dicaments dans les parcours de soins des patients atteints de CRSwNP, avec ou sans asthme comorbide. T\u00e9l\u00e9chargez-le d\u00e8s maintenant pour obtenir l\u2019int\u00e9gralit\u00e9 des informations. ARTICLE EN ACC\u00c8S LIBRE","og_url":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","og_image":[{"url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Indications-for-Biological-treatment-in-patients-with-CRSwNP_0-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/","url":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/","name":"Consensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","datePublished":"2019-05-15T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20Consensus20on20Biologics20for20CRSwNP20with20or20without20Asthma20Teaser.png","width":427,"height":280},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/news\/consensus-euforea-sur-les-biomedicaments-pour-la-crswnp-avec-ou-sans-asthme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"Consensus EUFOREA sur les biom\u00e9dicaments pour la CRSwNP avec ou sans asthme"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/30869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=30869"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/30869\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/30889"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=30869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=30869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=30869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}